|
US20070244120A1
(en)
*
|
2000-08-18 |
2007-10-18 |
Jacques Dumas |
Inhibition of raf kinase using substituted heterocyclic ureas
|
|
EP1158985B1
(en)
|
1999-01-13 |
2011-12-28 |
Bayer HealthCare LLC |
OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
WO2001047922A2
(en)
|
1999-12-24 |
2001-07-05 |
Aventis Pharma Limited |
Azaindoles
|
|
DK1268472T3
(da)
|
2000-02-07 |
2004-12-06 |
Bristol Myers Squibb Co |
3-aminopyrazolinhibitorer af cyclinafhængige kinaser
|
|
JP2004507455A
(ja)
|
2000-04-25 |
2004-03-11 |
ブリストル−マイヤーズ スクイブ カンパニー |
サイクリン依存性キナーゼ阻害剤としての、５−チオ−、スルフィニル−およびスルホニルピラゾロ［３，４−ｂ］−ピリジンの用途
|
|
NZ523656A
(en)
*
|
2000-08-31 |
2004-11-26 |
Pfizer Prod Inc |
Pyrazole derivatives and their use as protein kinase inhibitors
|
|
AU2002215053A1
(en)
*
|
2000-11-27 |
2002-06-24 |
Pharmacia Italia S.P.A. |
Phenylacetamido- pyrazole derivatives and their use as antitumor agents
|
|
GB0115109D0
(en)
|
2001-06-21 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
|
WO2003047579A1
(en)
*
|
2001-12-03 |
2003-06-12 |
Bayer Pharmaceuticals Corporation |
Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
|
|
US20050113283A1
(en)
*
|
2002-01-18 |
2005-05-26 |
David Solow-Cordero |
Methods of treating conditions associated with an EDG-4 receptor
|
|
SI1478358T1
(sl)
|
2002-02-11 |
2013-09-30 |
Bayer Healthcare Llc |
Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
|
|
KR20030071029A
(ko)
*
|
2002-02-27 |
2003-09-03 |
주식회사 팜제니아 |
항암제 및 방사선 치료 증진제로서 유용한 조성물
|
|
US20030225089A1
(en)
*
|
2002-04-10 |
2003-12-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
|
|
DE10221052A1
(de)
*
|
2002-05-10 |
2003-12-04 |
Transmit Technologietransfer |
Wirkstoffe zu Therapie, Diagnostik und Prophylaxe von Erkrankungen, bei denen abnorme Proteinstrukturen auftreten
|
|
MXPA04011417A
(es)
*
|
2002-05-17 |
2005-02-14 |
Pharmacia Italia Spa |
Derivados de aminoindazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
|
|
AU2003256755A1
(en)
|
2002-07-24 |
2004-02-09 |
Ptc Therapeutics, Inc. |
Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
|
|
CN100497302C
(zh)
*
|
2002-09-05 |
2009-06-10 |
神经研究公司 |
二芳基脲衍生物和它们作为氯通道阻滞剂的用途
|
|
MXPA05003432A
(es)
|
2002-10-09 |
2005-07-05 |
Pfizer Prod Inc |
Compuestos pirazoles para el tratamiento de trastornos neurodegenerativos.
|
|
UA81790C2
(uk)
|
2002-12-19 |
2008-02-11 |
Фармация Италия С.П.А. |
Заміщені піролопіразольні похідні як інгібітори кінази
|
|
US7557129B2
(en)
|
2003-02-28 |
2009-07-07 |
Bayer Healthcare Llc |
Cyanopyridine derivatives useful in the treatment of cancer and other disorders
|
|
GB0305426D0
(en)
*
|
2003-03-08 |
2003-04-16 |
Glaxo Group Ltd |
Novel compounds
|
|
EP1636585B2
(en)
|
2003-05-20 |
2012-06-13 |
Bayer HealthCare LLC |
Diaryl ureas with kinase inhibiting activity
|
|
BR122019010200B8
(pt)
|
2003-05-22 |
2021-07-27 |
Nerviano Medical Science S R L |
compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas
|
|
US7141568B2
(en)
|
2003-07-09 |
2006-11-28 |
Pfizer Italia S.R.L. |
Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
|
|
EP1663978B1
(en)
|
2003-07-23 |
2007-11-28 |
Bayer Pharmaceuticals Corporation |
Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
|
TW200526204A
(en)
|
2004-02-03 |
2005-08-16 |
Pharmacia Italia Spa |
1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
|
|
US7244757B2
(en)
*
|
2004-04-01 |
2007-07-17 |
Pfizer Inc |
Pyrazole-amine compounds for the treatment of neurodegenerative disorders
|
|
EP1609789A1
(en)
*
|
2004-06-23 |
2005-12-28 |
Eli Lilly And Company |
Ureido-pyrazole derivatives and their use as kinase inhibitors
|
|
EA012119B1
(ru)
*
|
2004-08-12 |
2009-08-28 |
Пфайзер Инк. |
ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНСУЛЬФАНИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ p38 MAP КИНАЗЫ
|
|
NZ590148A
(en)
|
2004-12-30 |
2012-04-27 |
Janssen Pharmaceutica Nv |
Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
|
|
US20060183758A1
(en)
*
|
2005-02-17 |
2006-08-17 |
Cb Research And Development, Inc. |
Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
|
|
US7429800B2
(en)
*
|
2005-06-30 |
2008-09-30 |
Sabic Innovative Plastics Ip B.V. |
Molding composition and method, and molded article
|
|
JP5303271B2
(ja)
|
2005-07-19 |
2013-10-02 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
キナーゼ阻害剤として有用な１Ｈ−チエノ［２，３−ｃ］ピラゾール化合物
|
|
AR059826A1
(es)
*
|
2006-03-13 |
2008-04-30 |
Univ California |
Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
|
|
JP2009535388A
(ja)
*
|
2006-05-03 |
2009-10-01 |
アストラゼネカ アクチボラグ |
ピラゾール誘導体、及びそのｐｉ３ｋ阻害薬としての使用
|
|
CN101573352A
(zh)
*
|
2006-10-21 |
2009-11-04 |
艾博特股份有限两合公司 |
杂环化合物和其作为糖原合酶激酶3抑制剂的用途
|
|
TW200901974A
(en)
|
2007-01-16 |
2009-01-16 |
Wyeth Corp |
Compounds, compositions, and methods of making and using them
|
|
WO2008128986A1
(en)
*
|
2007-04-18 |
2008-10-30 |
Probiodrug Ag |
Urea derivatives as glutaminyl cyclase inhibitors
|
|
AU2008263166A1
(en)
*
|
2007-05-25 |
2008-12-18 |
Janssen Pharmaceutica N.V. |
Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
|
|
EP2163541A1
(en)
*
|
2008-09-12 |
2010-03-17 |
Bayer Schering Pharma Aktiengesellschaft |
Piperazine derivatives for binding and imaging amyloid plaques and their use
|
|
CN102231983A
(zh)
*
|
2008-10-01 |
2011-11-02 |
北卡罗来纳大学查珀尔希尔分校 |
使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
|
|
US8461159B2
(en)
|
2008-11-25 |
2013-06-11 |
Jannsen Pharmaceutica BV |
Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
|
|
WO2010068452A1
(en)
*
|
2008-11-25 |
2010-06-17 |
Janssen Pharmaceutica Nv |
Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
|
|
JP2012526850A
(ja)
|
2009-05-13 |
2012-11-01 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
サイクリン依存性キナーゼ阻害剤及びその用法
|
|
US8901111B2
(en)
|
2009-06-05 |
2014-12-02 |
Janssen Pharmaceutica Nv |
Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase
|
|
US20120083476A1
(en)
|
2009-06-05 |
2012-04-05 |
Janssen Pharmaceutica Nv |
Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
|
|
WO2012054093A2
(en)
|
2010-01-29 |
2012-04-26 |
The Regents Of The University Of California |
Acyl piperidine inhibitors of soluble epoxide hydrolase
|
|
UA108233C2
(uk)
|
2010-05-03 |
2015-04-10 |
|
Модулятори активності гідролази амідів жирних кислот
|
|
AU2011274369A1
(en)
*
|
2010-07-02 |
2012-12-06 |
Ventana Medical Systems, Inc. |
Hapten conjugates for target detection
|
|
AU2011291034A1
(en)
*
|
2010-08-20 |
2013-03-14 |
Grünenthal GmbH |
Substituted cyclic carboxamide and urea derivatives as ligands of the vanilloid receptor
|
|
MX336726B
(es)
|
2010-09-27 |
2016-01-27 |
Abbott Gmbh & Co Kg |
Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
|
|
WO2012068381A2
(en)
|
2010-11-17 |
2012-05-24 |
The University Of North Carolina At Chapel Hill |
Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
|
|
US8541576B2
(en)
|
2010-12-17 |
2013-09-24 |
Nerviano Medical Sciences Srl |
Substituted pyrazolo-quinazoline derivatives as kinase inhibitors
|
|
US9090592B2
(en)
|
2010-12-30 |
2015-07-28 |
AbbVie Deutschland GmbH & Co. KG |
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
|
|
CA2835835C
(en)
|
2011-05-13 |
2019-04-02 |
Array Biopharma Inc. |
Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
|
|
AR087701A1
(es)
*
|
2011-08-31 |
2014-04-09 |
Japan Tobacco Inc |
Derivados de pirazol con actividad inhibidora de sglt1
|
|
WO2014078372A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
|
US9981959B2
(en)
|
2012-11-13 |
2018-05-29 |
Array Biopharma Inc. |
Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
|
WO2014078378A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
|
WO2014078328A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
|
RS55593B1
(sr)
|
2012-11-13 |
2017-06-30 |
Array Biopharma Inc |
Jedinjenja biciklične uree, tiouree, guanidina i cijanoguanidina korisna za lečenje bola
|
|
US9822118B2
(en)
|
2012-11-13 |
2017-11-21 |
Array Biopharma Inc. |
Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
|
MX374242B
(es)
|
2012-11-13 |
2025-03-05 |
Array Biopharma Inc |
Compuestos de n-pirrolidinil, n' -pirazolil-urea, tiourea, guanidina y cianoguanidina como inhibidores de trka cinasa.
|
|
WO2014078417A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
|
WO2014078331A1
(en)
*
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
|
WO2014078325A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
|
CA2906157C
(en)
|
2013-03-15 |
2022-05-17 |
G1 Therapeutics, Inc. |
Highly active anti-neoplastic and anti-proliferative agents
|
|
ME03557B
(me)
|
2013-03-15 |
2020-07-20 |
G1 Therapeutics Inc |
Privremena zaštiтa normalnih ćelija током hemoterapije
|
|
WO2015161288A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents
|
|
MA40434B1
(fr)
|
2014-05-15 |
2019-09-30 |
Array Biopharma Inc |
1-((3s,4r)-4-(3-fluorophényl)-1-(2-méthoxyéthyl)pyrrolidin-3-yl)-3-(4-méthyl-3-(2-méthylpyrimidin-5-yl)-1-phényl-1h-pyrazol-5-yl)urée comme inhibiteur de la kinase trka
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
EP3191098A4
(en)
|
2014-09-12 |
2018-04-25 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
WO2020252240A1
(en)
*
|
2019-06-14 |
2020-12-17 |
Ifm Due, Inc. |
Compounds and compositions for treating conditions associated with sting activity
|
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
|
WO2022135442A1
(zh)
*
|
2020-12-22 |
2022-06-30 |
上海拓界生物医药科技有限公司 |
Cdk2抑制剂及其制备方法
|
|
EP4274824A1
(en)
|
2021-01-08 |
2023-11-15 |
IFM Due, Inc. |
Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
|